Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Collagen type X alpha 1 chain (COL10A1)
- Target
- COL10A1
- Molecular classification
- Other (Short-chain collagen, extracellular matrix protein)
01
Overview
Collagen type X alpha 1 chain (COL10A1) is a short-chain, homotrimeric collagen expressed mainly by hypertrophic chondrocytes during endochondral ossification, regulating mineralization zones in cartilage and playing a vital role in skeletal development[1][2][3][5]. Mutations in COL10A1 cause Schmid metaphyseal chondrodysplasia, a skeletal dysplasia characterized by growth plate abnormalities[1][3]. Research shows that upregulation of COL10A1 is associated with poor prognosis and tumor progression in several cancer types, where it activates pathways including TGF-β/Smad, MEK/ERK, and FAK, and facilitates epithelial–mesenchymal transition, extracellular matrix remodeling, and tumor-stroma communication[2]. Although it is not yet an established drug target, COL10A1 is emerging as a potential biomarker for cancer diagnosis, prognosis, and bone/cartilage growth assessment[1][2].
- Other names
- Collagen alpha-1(X) chainCollagen X alpha 1Collagen type X α 1 chainCOL XCN10Col10Collagen, type X, alpha 1Schmid metaphyseal chondrodysplasia (context: disease association)Collagen, type X, α 1Collagen X α 1
02
Mechanism of action
Not applicable; COL10A1 is not presently a direct drug target. Mechanistically, it modulates various tumorigenic pathways (TGF-β/Smad, MEK/ERK, FAK) as a matrix component and ligand[2].
03
Biological functions
Extracellular matrix organization[1][2][5]Cartilage development and endochondral ossification[1][2][5]Regulation of mineralization zones in hyaline cartilage[5]Cellular signaling via interaction with cell surface receptors (e.g., DDR2, integrins)[2]
04
Disease associations
Cancer (e.g., upregulated in lung, gastric, pancreatic, colorectal, and breast cancers, associated with tumor progression, invasion, and metastasis)[2]Bone dysplasia (Schmid metaphyseal chondrodysplasia, Japanese type spondylometaphyseal dysplasia)[1][3]Potential biomarker for bone/cartilage growth and healing assessment[1]
05
Safety considerations
No specific safety concerns noted, as COL10A1 is not a direct therapeutic target. Challenges exist in targeting structural matrix proteins due to their widespread physiological roles and potential impact on normal tissue homeostasis[2].
06
Interacting drugs
None currently approved or clinically validated as direct COL10A1 modulators[2].
07
Biomarkers
CXM (degradation byproduct of COL10A1, used as a marker for growth velocity and fracture healing)[1]COL10A1 serum levels (investigational, for detection of colon and other cancers)[1][2]
Beyond the preview
Go deeper on Collagen type X alpha 1 chain (COL10A1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Collagen type X alpha 1 chain (COL10A1).